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Abstract Estrogen catabolism is a major function of
CYP2C19. The effect of CYP2C19 polymorphisms on
tamoxifen sensitivity may therefore not only be mediated by
a variation in tamoxifen metabolite levels but also by an
effect on breast cancer risk and molecular subtype due to
variation in lifelong exposure to estrogens. We determined
the association between these polymorphisms and tamoxifen
sensitivity in the context of a randomized trial, which allows
for the discernment of prognosis from prediction. We
isolated primary tumor DNA from 535 estrogen receptor-
positive, stages I–III, postmenopausal breast cancer patients
who had been randomized to tamoxifen (1–3 years) or no
adjuvant therapy. Recurrence-free interval improvement
with tamoxifen versus control was assessed according to the
presence or absence of CYP2C19*2 and CYP2C19*17.
Hazard ratios and interaction terms were calculated using
multivariate Cox proportional hazard models, stratified for
nodal status. Tamoxifen benefit was not significantly affec-
ted by CYP2C19*17. Patients with at least one CYP2C19*2
allele derived significantly more benefit from tamoxifen (HR
0.26; p = 0.001) than patients without a CYP2C19*2 allele
(HR 0.68; p = 0.18) (p for interaction 0.04). In control
patients, CYP2C19*2 was an adverse prognostic factor. In
conclusion, breast cancer patients carrying at least one
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CYP2C19*2 allele have an adverse prognosis in the absence
of adjuvant systemic treatment, which can be substantially
improved by adjuvant tamoxifen treatment.
Keywords Breast cancer  CYP2C19  Estrogen
catabolism  Tamoxifen metabolism  Endocrine resistance
Background
Although polymorphisms in CYP450 enzymes are exten-
sively studied in the context of drug metabolism, the pri-
mary physiologic role of these enzymes is the metabolism
of endogenous steroids, like catabolism of estrogens [1].
Thereby, in breast cancer patients, a potentially observed
effect of a CYP450 polymorphism on tamoxifen sensitivity
may not only be mediated by variation in tamoxifen
metabolite levels but also possibly by variation in lifelong
exposure to estrogens that affect tumorigenesis.
CYP2C19 is a typical example of a CYP450 enzyme
that affects both metabolism of tamoxifen to 4-hy-
droxytamoxifen [2] as well as estrone (E1) and estradiol
(E2) catabolism [1]. In addition, CYP2C19 has been
shown to catalyze metabolism of testosterone [3]. Both
estrogens and testosterone have been demonstrated to
affect the risk of estrogen receptor a (ERa)-positive
breast cancer in postmenopausal women [4]. Relatively
frequent CYP2C19 polymorphisms are the (non-func-
tional) CYP2C19*2 variant, with a minor allele fre-
quency of 13 % in healthy Caucasians [5], and the
(ultra-active) CYP2C19*17 variant, with a minor allele
frequency of around 20 % [6]. Previously, it has been
shown in postmenopausal breast cancer patients that
genetic variation in CYP2C19 affects estrone levels [7].
The highest estrone levels were found in patients who
were either heterozygous or homozygous for the
CYP2C19*2 allele, while the ultrarapid variant of this
enzyme, CYP2C19*17, was associated with low estrone
levels [7] and decreased breast cancer risk [8].
Estrogens are not only associated with breast cancer risk
but also possibly influence breast cancer molecular subtype
[9], and therefore polymorphisms that affect estrogen lev-
els might have an effect on breast cancer prognosis and
drug sensitivity. Intriguingly, both the non-functional
CYP2C19 variant as well as the ultrarapid variant have
been associated with favorable outcomes after endocrine
therapy. CYP2C19*2 was associated with a favorable
progression-free survival in patients with metastatic breast
cancer treated with tamoxifen [10], while carriers of a
CYP2C19*17 allele who were treated with adjuvant
tamoxifen had a favorable disease-free survival compared
to non-CYP2C19*17 carriers [11]. A general methodolog-
ical flaw in studies which analyze the polymorphism in
consecutive series of patients treated with the same drug is
that the predictive value of these polymorphisms with
respect to drug sensitivity cannot be discriminated from the
prognostic value. Therefore, the optimal method of dis-
cerning a predictive marker from a prognostic marker is
within a randomized clinical trial.
The aim of our study was to analyze the predictive and
prognostic value of genetic polymorphisms in CYP2C19 in
postmenopausal breast cancer patients, randomized between
adjuvant tamoxifen and no systemic treatment.
Methods
Patients and material
From 1982 to 1994, a randomized clinical trial was con-
ducted in the Netherlands, studying the benefit from adjuvant
tamoxifen (IKA-trial) versus no adjuvant therapy [12, 13].
Study data were part of the Oxford meta-analysis [14].
Patients were randomized in a 2:1 ratio between 1-year
tamoxifen (30 mg per day) and no adjuvant therapy. Eligible
patients were postmenopausal,\76 years of age, and had a
T1–4, N0–3, M0 breast tumor [15] with no mastitis or palpable
supra- or infraclavicular lymph nodes. After 1 year, for
patients in the tamoxifen arm who were on study, a second
randomization was performed to receive another 2 years of
tamoxifen or to stop further treatment. From 1989, based on
two interim analyses showing a significant improvement
in recurrence-free survival among lymph node-positive
patients, these node-positive patients were all allocated to the
tamoxifen treatment arm (i.e., skipped the first randomiza-
tion). In total, 1,662 patients were included. The patient
characteristics and clinical outcome of tamoxifen treatment
have been presented elsewhere [13].
We have traced tissue blocks of participating patients
and recollected sufficient tumor material of 739 patients
who did not differ in prognostic factors from the total
group (Table S1). After revision of estrogen receptor a
(ERa) status as assessed with immunohistochemistry
(IHC), a total of 563 ERa-positive tumors were used for
subsequent analysis. The number of patients in each
treatment arm of randomization 1 and randomization 2,
pre- and post-interim analysis, is shown in Figure S1.
Immunohistochemistry
Tissue microarrays (TMAs) were constructed using for-
malin-fixed paraffin-embedded (FFPE) tumor blocks. The
TMAs were stained for ERa, progesterone receptor (PgR),
and HER2. ERa and PgR were considered positive when
C10 % of invasive cells showed nuclear reactivity. This
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cutoff was chosen because it is common practice in the
Netherlands and in addition this would avoid the potential
inclusion of basal-like tumors [16] in our analysis. HER2
was considered positive when membranous staining was
score 3. In case of a membranous score of 2, chromogenic
in situ hybridization (CISH) was performed on whole-tis-
sue slides. For tumors that did not have sufficient cores in
the TMA, whole slides were cut and could adequately be
assessed for ERa (N = 60), PgR (N = 55), and HER2
(N = 36). Tumor grade was scored on a hematoxylin–
eosin (HE)-stained slide using the modified Bloom–Rich-
ardson score [17].
DNA isolation
From paraffin-embedded tissue blocks, 10-lM-thick sec-
tions were cut and attached to microscope slides. A total of
10 slides per tumor were used for DNA isolation. Slides
were deparaffinized in xylene, rehydrated, and stained with
hematoxylin. The slides were incubated with sodiumthio-
cyanate overnight. Exact tumor location was circled by the
pathologist on a HE-stained slide, which was used as a
template. After adding a drop of tissue lysis buffer, tumor
tissue was scraped from the slides, added to a 1.5-ll micro-
centrifuge tube containing a 200-ll mix of tissue lysis
buffer/proteinase K. This tube was incubated in a Ther-
momixer at 55 C for 48 h. An additional 27-ll proteinase
K (2 mg/ll) was added after 24 and 36 h. After 48 h, the
tube was incubated at 80 C for 10 min to inactivate pro-
teinase K. After centrifuging, the supernatant was pipetted
into a new tube. A total of 150 ll was purified using a
QIAquick PCR purification kit. DNA isolation was suc-
cessful for 535 tumor samples.
Genotyping
Genotyping for CYP2C19*2 (681G[A, rs4244285) and
CYP2C19*17 (-806C[T, rs12248560) was performed on
tumor DNA. The concordance between selected genotyp-
ing from FFPE-derived tumor DNA and DNA from serum
has previously been established [18]. Taqman allelic dis-
crimination assays were used (Applied Biosystems, Nieu-
werkerk ad IJssel, The Netherlands) on an ABI Prism 7500
Sequence Detection system (Applied Biosystems). Each
assay consisted of two allele-specific minor groove-binding
(MGB) probes, labeled with fluorescent dyes VIC and
FAM. The assay IDs are C_25986767_70 (CYP2C19*2)
and C_469857_10 (CYP2C19*17). Thermal profile for
genotyping consisted of 95 C for 10 min, followed by 50
cycles of 15 s at 92 C and 90 s at 60 C. Genotypes were
scored by allele-specific fluorescence using 7500 fast sys-
tem SDS software (Applied Biosystems).
Statistics
Recurrence-free interval (RFI) was taken as the time from
the date of (first) randomization until the occurrence of a
local, regional, or distant recurrence or breast cancer-spe-
cific death [19]. Since these CYP2C19 variants are asso-
ciated with breast cancer risk and the duration of treatment
in this trial was relatively short to prevent the occurrence of
a secondary breast cancer, patients with a secondary con-
tra-lateral breast cancer were censored at the date of this
occurrence (Table S2). In the subset of 563 ERa-positive
patients, median follow-up of patients without a recurrence
event is 7.8 years. Genotypes were tested for Hardy–
Weinberg equilibrium using a Chi square test. The distri-
bution of clinico-pathological characteristics by the
CYP2C19*2 and CYP2C19*17 variants was evaluated
using Chi square tests. Survival curves were constructed
using the Kaplan–Meier method and compared using log-
rank tests. To determine whether the benefit from tamox-
ifen was different in CYP2C19 (one or two *2 alleles vs. no
*2 allele and one or two CYP2C19*17 alleles vs. no
CYP2C19*17 allele) genotypes, covariate adjusted Cox
proportional hazard regression models were constructed
with an interaction between the treatment and the geno-
type. Treatment groups were defined according to the
results of the first randomization (1–3 years of tamoxifen
versus no adjuvant systemic treatment). The change in
randomization that occurred after the interim analysis
resulted in an enrichment of lymph node-positive patients
in the group of tamoxifen-treated patients. Therefore, Cox
proportional hazard regression models were stratified for
nodal status. The following factors were included as
covariates: age (C65 vs. \65), grade (grade 3 vs. grade
1–2), tumor size (T3–T4 vs. T1–T2), HER2 status (positive
versus negative), estrogen receptor expression (10–99 vs.
100 %), and progesterone status (positive versus negative).
No adjustments for multiple testing were performed. To
assess the prognostic value of the CYP2C19 genotypes, we
performed covariate adjusted Cox proportional hazard
regression (including lymph node status) in the subgroup of
patients who were randomized to the control arm. This
study complied with reporting recommendations for the
tumor marker prognostic studies (REMARK) criteria [20]
outlined in Table S3.
Results
Study population and genotypes
Adequate genotype data for CYP2C19*2 and CYP2C19*17
were available for 494 and 504 patients, respectively (Fig.
S2). For CYP2C19*2, a total of 12 (2.4 %) patients were
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homozygous carrier and 127 (25.7 %) heterozygous carri-
ers were found. The homozygote CYP2C19*17/*17 geno-
type was seen in 28 (5.6 %) of the patients, while 151
(30.0 %) were heterozygous. Genotype frequencies of
CYP2C19*2 and CYP2C19*17 were in Hardy–Weinberg
equilibrium (p = 0.86 and p = 0.06, respectively). A weak
association between CYP2C19*2 and low ERa expression
was observed (Table 1). A higher frequency of grade III
was observed in patients carrying a CYP2C19*17 allele.
(Table S4). In general, known prognostic factors were
equally divided over the treatment arms for all genotypes
(Tables S5, 6), with the exception of lymph node status
which can be explained by the change in randomization. In
patients without a CYP2C19*17 allele, the tamoxifen arm
included more HER2-positive patients than the control
arm, while in patients with a CYP2C19*17 allele, the
patients in the control arm were younger than the patients
in the tamoxifen arm.
Association of genotypes with tamoxifen response
in ERa-positive patients
When stratified by nodal status, the tamoxifen effect in all
563 ERa-positive patients is 0.54 (95 % CI 0.36–0.83,
p = 0.004). In univariate analysis, positive lymph node
status was associated with an unfavorable outcome (HR
2.61, p \ 0.001). No significant interaction between lymph
node status and tamoxifen was observed.
We did not find a significant interaction between the
CYP2C19*17 genotype and treatment (adjusted p for
interaction = 0.62) (Table S7). However, a significant
interaction between CYP2C19*2 genotype and treatment
was found (both unadjusted and adjusted p for interac-
tion = 0.04). Patients carrying one or two CYP2C19*2
alleles derived more benefit from tamoxifen than patients
with no CYP2C19*2 allele (CYP2C19*2 carriers: adjusted
HR = 0.26, p = 0.001; non-CYP2C19*2 carriers: adjusted
HR = 0.64, p = 0.18; Figs. 1 and S3; Table 2). Perform-
ing a sensitivity analysis, using a 3-level factor for T-stage
(T1, T2, and T3–4), did not substantially change these
results (Table S8).
Tamoxifen-untreated patients with a CYP2C19*2 vari-
ant allele (N = 33) had an unfavorable RFI when com-
pared with tamoxifen-untreated patients without a
CYP2C19*2 allele (N = 86). After correcting for the
prognostic factors as described in the methods section,
CYP2C19*2 remained an independent adverse prognostic
factor (HR = 2.77, p = 0.01) (Table S9). We did not find a
difference in RFI in control patients with a CYP2C19*17
allele (p = 0.91) (Table S10).
Conclusion and discussion
In this study population, postmenopausal breast cancer
patients with a CYP2C19*2 variant allele had a worse
prognosis, but derived more benefit from adjuvant tamoxifen
treatment compared to patients without a CYP2C19*2 allele.
Previously, others have found discordant effects of
CYP2C19*2 with respect to outcome after tamoxifen
treatment. Okishiro et al. [21] found a favorable recur-
rence-free survival for Japanese patients treated with
adjuvant tamoxifen who were homozygous for
CYP2C19*2 or CYP2C19*3 variants, compared with
patients with heterozygote or wild-type phenotype,
although this difference was not significant (HR = 0.37,
Table 1 Distribution of CYP2C19*2 carriers according to clinico-
pathological variables
cyp2C19*2 genotype p valuea
Total No *2
allele
One or two *2
alleles
N N (%) N (%)
494 354 (100) 140 (100)
Age
\65 237 170 (48) 67 (48) 0.97
C65 257 184 (52) 73 (52)
Treatment
Control 119 86 (24) 33 (24) 0.30b
Tamoxifen 1 year 230 171 (48) 59 (42)
Tamoxifen 3 years 145 97 (27) 48 (34)
Lymph node status
Negative 271 202 (57) 69 (49) 0.12
Positive 223 152 (43) 71 (51)
Tumor size
T1–T2 439 316 (89) 123 (88) 0.65
T3–T4 55 38 (11) 17 (12)
Grade
I–II 322 225 (64) 97 (69) 0.23
III 172 129 (36) 43 (31)
Estrogen receptor
Low (0–90 %) 128 83 (23) 45 (32) 0.05
High (100 %) 366 271 (77) 95 (68)
Progesterone receptor
Negative 230 164 (46) 66 (47) 0.87
Positive 254 184 (52) 70 (50)
Missing 10 6 (2) 4 (3)
HER2
Negative 428 302 (85) 126 (90) 0.15
Positive 38 31 (9) 7 (5)
Missing 28 21 (6) 7 (5)
a Chi square test, analysis based on cases without missing values
b Chi square test for trend
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p = 0.21). The number of patients in that study was rela-
tively small (N = 173) and the comparison that was made
was different from our analysis, since we grouped homo-
zygous and heterozygous CYP2C19*2 carriers together. In
a study from van Schaik et al. [10], the CYP2C19*2 variant
was assessed in three independent series of patients who
were treated with tamoxifen for metastatic breast cancer.
An increased time to treatment failure was observed for
patients with the CYP2C19*2 variant. Ruiter et al. [22]
analyzed CYP2C19*2 in a Dutch population-based cohort
study. In this study, a subset of 80 female breast cancer
patients who were treated with tamoxifen (adjuvant or
palliative), CY2C19*2 carriers, had a better survival
(HR = 0.26, p = 0.03). However, in a series of patients
who were all treated with adjuvant tamoxifen, Schroth
et al. [11] observed an unfavorable outcome for patients
carrying a CY2C19*1, *2, or *3 allele compared to patients
with a CYP2C19*17 allele. Since none of the above-
mentioned studies included a (matched) control group, the
predictive value of the polymorphism cannot be discerned
from its prognostic value. In the adjuvant setting with
recurrence-free survival as the endpoint, the prognosis is
not only affected by the molecular subtype of the primary
tumor but also by the occurrence of secondary primary
breast cancer. Since CYP2C19*2 and CYP2C19*17 have
been associated with, respectively, increased and decreased
breast cancer risk [8], this might also affect the occurrence
of secondary breast tumors, particularly in the case of
relatively long follow-up. In addition, CYP2C19 variants
might influence breast cancer prognosis by their lifelong
affect on estrogen levels, which might potentially influence
breast cancer molecular subtype [9].
We observed in our series that the CYP2C19*2 variant
was associated with unfavorable prognosis. In the series of
Ruiter et al., CYP2C19*2 was not significantly associated
with breast cancer mortality in patients not using tamoxi-
fen. We exclusively analyzed ERa-positive patients which
may explain the inconsistency in our findings and those of
Ruiter et al. To our knowledge, there are no other studies
that analyzed the effect of this CYP2C19 variant on breast
cancer prognosis.
Several explanations for the increased benefit from
tamoxifen in patients who carry a CYP2C19*2 allele can be
considered. Since the presence of this non-functional allele
would expectedly result in a decrease in active metabolites
and a reduced tamoxifen benefit, simply the variation in
active tamoxifen metabolite levels is not an obvious
explanation. Previously, it had been suggested that reduced
isomerization of trans-endoxifen into the less potent cis-
endoxifen in patients with a CYP2C19*2 allele may result
in an increased response to tamoxifen therapy [10]. Since
we did not observe an opposite association with tamoxifen
response for patients carrying the highly active
CYP2C19*17 variant, this is not likely the case. Moreover,
CYP2C19 polymorphisms do not seem to significantly
affect tamoxifen metabolite levels in breast cancer patients
[23], which also argues against an effect mediated by
tamoxifen metabolism.
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Fig. 1 Kaplan–Meier survival analysis for recurrence-free interval
according to tamoxifen treatment in patients without a CYP2C19*2
allele (a) and patients with a CYP2C19*2 allele (b). Hazard ratios,
95 % confidence intervals, and p values were based on multivariate
Cox regression analysis, stratified for nodal status
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It is more likely that women carrying a CYP2C19*2
genotype are susceptible to tumors that are highly depen-
dent on estrogen signaling due to their lifelong higher
exposure to estrogens [7] and would therefore be more
sensitive to estrogen-inhibiting therapy. Since we did not
have serum available from patients who participated in this
trial, we were not able to obtain supportive data for this
hypothesis in our series. We also did not have gene
expression data available to test whether patients with a
CYP2C19*2 variant had a different molecular subtype.
We did not correct for multiple testing. In early stage
research, the concern is both to avoid type II as well as type
I errors. It would be interesting to confirm our observations
and further explore our hypothesis in randomized series of
patients from whom genotype, gene expression, and serum
are available, treated with and without anti-estrogens.
Another limitation of our study is the relatively short
duration of tamoxifen therapy (1–3 years) in this retro-
spectively analyzed randomized trial. Currently, a minimal
duration of 5 years is common clinical practice; however, we
anticipate that the relative effects of the genotypes analyzed
in this study will be similar for shorter and longer durations
of endocrine therapy. The patients in our study randomized
to adjuvant treatment received tamoxifen only (and no aro-
matase inhibitors), while currently most ERa-positive,
postmenopausal breast cancer patients receive an aromatase
inhibitor preceding or following tamoxifen treatment. Since
we hypothesize that tumors from women with a CYP2C19*2
genotype are highly dependent on estrogen signaling, we
expect an increased benefit from aromatase inhibitors as well
in these patients. It would be interesting to analyze this
question in randomized trials comparing aromatase inhibi-
tion with tamoxifen. The patients in our trial had not received
adjuvant chemotherapy, and thereby the observed effect of
the CYP2C19 genotype was not biased by adjuvant chemo-
therapy that might have cured endocrine-resistant patients.
In summary, CYP2C19 is primarily involved in
endogenous steroid metabolism and may therefore influ-
ence tumorigenesis and sensitivity to endocrine therapy
which has not yet been appreciated. We show that the
presence of a CYP2C19*2 variant allele identifies those
ERa-positive postmenopausal breast cancer patients who
have an adverse prognosis, but will derive substantial
benefit from adjuvant tamoxifen.
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